ストックスクリーナーアプリを入手
7.05
1.26%
-0.09
前日終値:
$7.14
開ける：
$7.14
24時間の取引高:
601.39K
Relative Volume:
0.44
時価総額：
$543.93M
収益：
-
当期純損益:
$-168.09M
株価収益率:
-3.2488
EPS:
-2.17
ネットキャッシュフロー:
$-138.01M
1週間 パフォーマンス:
-10.08%
1か月 パフォーマンス:
-7.84%
6か月 パフォーマンス:
-63.88%
1年 パフォーマンス:
-66.95%
1日の値動き範囲:
$6.96
$7.22
1週間の範囲:
$6.96
$7.87
52週間の値動き範囲:
$6.79
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
名前
Kura Oncology Inc
セクター
電話
(858) 500-8800
住所
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
KURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.05 | 543.93M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-14 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-08-11 | 開始されました | BofA Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-05-17 | 開始されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2022-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 開始されました | Jefferies | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-11-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-11-09 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-13 | 再開されました | Leerink Partners | Outperform |
| 2016-01-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-30 | 開始されました | Oppenheimer | Outperform |
| 2015-12-16 | 開始されました | Citigroup | Buy |
すべてを表示
Kura Oncology Inc (KURA) 最新ニュース
Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Buy Rating - Defense World
Kura Oncology presents promising preclinical data By Investing.com - Investing.com South Africa
Kura Oncology presents promising preclinical data - Investing.com India
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting - The Manila Times
Breakthrough Cancer Drug Combination Shows Enhanced Antitumor Activity in Kidney Cancer - StockTitan
Charles Schwab Investment Management Inc. Buys 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Insider Sell: Faheem Hasnain Sells 22,682 Shares of Kura Oncology Inc (KURA) - GuruFocus.com
Kura Oncology director Hasnain Faheem sells $181,456 in shares By Investing.com - Investing.com South Africa
Kura Oncology director Hasnain Faheem sells $181,456 in shares - Investing.com
Bank of New York Mellon Corp Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Brokers Issue Forecasts for Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Hold” - Defense World
US Bancorp DE Has $193,000 Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
BTIG Research downgrades Kura Oncology Inc (KURA) stock to a Neutral - Knox Daily
Kura Oncology Inc (KURA) Q4 2024 Earnings: EPS of -$0.22 Beats E - GuruFocus.com
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies By Investing.com - Investing.com UK
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies - Investing.com
Kura Oncology stock hits 52-week low at $6.98 amid challenges - Investing.com Australia
Kura Oncology stock hits 52-week low at $6.98 amid challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA) - Defense World
UBS Group Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Metrics That Matter About Kura Oncology Inc (NASDAQ: KURA) - Stocks Register
Kura Oncology's Latest Strategic Move: 190K Share Options Package Draws Top Talent - StockTitan
Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Kura Oncology price target lowered to $14 from $27 at UBS - TipRanks
Cantor Fitzgerald Comments on Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Rating Increased to Buy at StockNews.com - Defense World
UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating -March 06, 2025 at 09:52 am EST - Marketscreener.com
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future - Investing.com India
Kura Oncology’s SWOT analysis: ziftomenib trials key for AML stock’s future By Investing.com - Investing.com South Africa
Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Industry Analysts Just Upgraded Their Kura Oncology, Inc. (NASDAQ:KURA) Revenue Forecasts By 62% - Simply Wall St
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity - Seeking Alpha
Brokers Issue Forecasts for Kura Oncology FY2026 Earnings - Defense World
FY2025 EPS Estimate for Kura Oncology Reduced by Analyst - Defense World
HC Wainwright Predicts Kura Oncology Q2 Earnings - Defense World
Wedbush Estimates Kura Oncology’s Q1 Earnings (NASDAQ:KURA) - Defense World
Kura Oncology’s (KURA) Outperform Rating Reiterated at Wedbush - Defense World
HC Wainwright Weighs in on Kura Oncology Q1 Earnings - Armenian Reporter
Brokers Offer Predictions for Kura Oncology Q1 Earnings - Armenian Reporter
Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns - TipRanks
Research Analysts Set Expectations for Kura Oncology Q1 Earnings - MarketBeat
Equities Analysts Issue Forecasts for Kura Oncology Q1 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Stock Rating Upgraded by StockNews.com - Defense World
Kura Oncology (NASDAQ:KURA) Upgraded at StockNews.com - MarketBeat
Kura Oncology (NASDAQ:KURA) Earns Outperform Rating from Wedbush - MarketBeat
Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago - Yahoo Finance
Kura Oncology’s Positive Earnings Call Highlights Progress and Prospects - TipRanks
Kura Oncology Inc (KURA) 財務データ
収益
当期純利益
現金流量
EPS
Kura Oncology Inc (KURA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hasnain Faheem | Director |
Mar 21 '25 |
Sale |
8.00 |
22,682 |
181,456 |
23,983 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):